Coherus BioSciences, Inc. (CHRS) Tuesday said it has agreed to buy back about $170 million of its 1.500% convertible senior subordinated notes due 2026 at its principal plus interest amount.
The buyback is conditioned upon the closing of the previously announced sale of the UDENYCA franchise following an agreement with Intas Pharmaceuticals Ltd.
The company also intends to repurchase the remaining notes after the closing of the buyback of about $60 million.
Additionally, Coherus said that the note holders party to the repurchases have agreed to provide their consent to adopt certain proposed amendments to the indenture.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.